German biotechnology company BioNTech SE (NASDAQ: BNTX) announced on Thursday that it has completed its exchange offer to acquire Germany-based biopharmaceutical company CureVac N.V. (NASDAQ: CVAC), following the expiry of the subsequent offering period.

The transaction is intended to strengthen BioNTech's capabilities in mRNA design, delivery formulations and mRNA manufacturing, supporting its oncology-focused strategy.

BioNTech said approximately 195 million CureVac shares, representing about 86.75% of the issued share capital, were validly tendered. The company expects to complete the compulsory acquisition of the remaining CureVac shares in January 2026 as part of the previously announced post-offer reorganisation, after which CureVac shares will cease trading.

CureVac will continue to operate under its existing organisational processes to ensure business continuity, while BioNTech undertakes strategic, operational and scientific reviews to define the future organisational and portfolio structure.

BioNTech said the acquisition builds on its position in the global mRNA industry and supports its oncology programmes, including mRNA-based cancer immunotherapies and pumitamig (BNT327/BMS986545), a bispecific antibody candidate jointly developed with Bristol Myers Squibb Company (NYSE: BMY).